• Citer

1446P Preliminary efficacy and safety of rilvegostomig (AZD2936), a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-pretreated advanced/metastatic non-small-cell lung cancer (NSCLC): ARTEMIDE-01

par Brandão, Mariana ;Hiltermann, J.T.J.N.;Wauters, Els;Solomon, B;Castanon Alvarez, E.;Felip, Enriqueta;Gort, E.H.;Izumi, H.;Kim, Dong Wook;Paz Ares, Luis;Rohrberg, Kristoffer;Steinbusch, L.;Yoshida, T.;Chen, H.;Colebrook, S.;Achour, I.;Origuchi, M.;Aroldi, F.;Cho, B.C.
Référence Annals of oncology, 34, page (S822-S823)
Publication Publié, 2023-10

Article révisé par les pairs

• Accès en ligne
• Détails
• Statistiques

Titre:	1446P Preliminary efficacy and safety of rilvegostomig (AZD2936), a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-pretreated advanced/metastatic non-small-cell lung cancer (NSCLC): ARTEMIDE-01
Auteur:	Brandão, Mariana; Hiltermann, J.T.J.N.; Wauters, Els; Solomon, B; Castanon Alvarez, E.; Felip, Enriqueta; Gort, E.H.; Izumi, H.; Kim, Dong Wook; Paz Ares, Luis; Rohrberg, Kristoffer; Steinbusch, L.; Yoshida, T.; Chen, H.; Colebrook, S.; Achour, I.; Origuchi, M.; Aroldi, F.; Cho, B.C.
Informations sur la publication:	Annals of oncology, 34, page (S822-S823)
Statut de publication:	Publié, 2023-10
Sujet CREF:	Cancérologie
Langue:	Anglais
Identificateurs:	urn:issn:0923-7534
	info:doi/10.1016/j.annonc.2023.09.2477
	info:pii/S0923753423033148